4//SEC Filing
Picularium, LLC 4
Accession 0000899243-20-019815
CIK 0001812364other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 5:34 PM ET
Size
12.4 KB
Accession
0000899243-20-019815
Insider Transaction Report
Form 4
Picularium, LLC
10% Owner
Transactions
- Conversion
Common Stock, par value $0.001 per share
2020-07-20+3,281,253→ 3,281,253 total - Conversion
Series A Preferred Stock, $0.001 par value per share
2020-07-20−9,999,999→ 0 total→ Common Stock,$0.001 par value per share (2,816,171 underlying) - Conversion
Series C Preferred Stock, $0.001 par value per share
2020-07-20−1,651,471→ 0 total→ Common Stock,$0.001 par value per share (465,082 underlying)
SHAW DAVID E
10% Owner
Transactions
- Conversion
Series C Preferred Stock, $0.001 par value per share
2020-07-20−1,651,471→ 0 total→ Common Stock,$0.001 par value per share (465,082 underlying) - Conversion
Series A Preferred Stock, $0.001 par value per share
2020-07-20−9,999,999→ 0 total→ Common Stock,$0.001 par value per share (2,816,171 underlying) - Conversion
Common Stock, par value $0.001 per share
2020-07-20+3,281,253→ 3,281,253 total
Footnotes (3)
- [F1]Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date.
- [F2]Each share of Issuer Series C Preferred Stock, $0.001 par value per share, automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .2985366 of a share of Common Stock for each share of Series C Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date.
- [F3]David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any.
Documents
Issuer
Relay Therapeutics, Inc.
CIK 0001812364
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001817110
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 5:34 PM ET
- Size
- 12.4 KB